You need to login...
If you are not registered...
| Subscribe to Krixos Health: | |
|
or call us on: +43 (0)1 27 63 015 or email: subscribe@krixos.com |
|
Most viewed
- 1. Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data.
- 2. Sexual activity in men undergoing ADT for localized prostate cancer: a narrative literature review.
- 3. Follow-up of hereditary endometrial carcinoma caused by MLH3 gene mutation: a case report
- 4. ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting
- 5. Accent Therapeutics Presents Data Supporting Therapeutic Potential of First-in-Class DHX9 Inhibitor, ATX-559, and Novel KIF18A Inhibitor, ATX-295, at the AACR Annual Meeting 2025
- 6. Association of aggregate index of systemic inflammation with increased all-cause and cardiovascular mortality in female cancer patients
- 7. LSM2 drives glioma progression through alternative splicing dysregulation: a multi-omics approach to identify a potential therapeutic target
- 8. Human medicines European public assessment report (EPAR): Dazublys, trastuzumab, Status: Opinion
- 9. Novartis posts better-than-expected sales driven by medicine demand
- 10. Why brain metastases of breast cancer resist a promising candidate therapy
Last updated at 21:05 GMT
Hot News Makers
Health/Pharma Companies
-
45420.26
-
15665.51
-
14387.05
-
13372.51
-
10784.67
-
7976.95
-
7845.88
-
6923.18
-
6828.58
-
6627.69
Drugs, Treatments, Trials
-
12248.84
-
11425.85
-
6912.11
-
6121.90
-
5512.28
-
4636.97
-
4261.45
-
3976.02
-
2947.80
-
2512.38
Last updated at 20:10 GMT
